Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198284 · ClinicalTrials.gov registry record
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
A clinical trial of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI.
- Active
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT05198284: Active study of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI.
NCT05198284 is a study of Chronic Kidney Diseases and Diabetic Kidney Disease that is active but no longer recruiting, run by Renalytix AI. The registered enrollment target is 2,000 participants, above the 417-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (380% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05198284, a study of Chronic Kidney Diseases and Diabetic Kidney Disease, is active but no longer recruiting, sponsored by Renalytix AI.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Primary Outcome
Proportion (target: 20% increase from prior measurements) of visits in which each participant achieves target blood pressure of \<140/90 mmHg (as per the NKF CKD management guidelines).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST KidneyIntelX
Study Locations (1)
New York
- Mount Sinai Health System - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-11-01 |
What the registry record for NCT05198284 still lists
NCT05198284 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 417-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (380% higher).
The record links to 5 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.
NCT05198284 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05198284 about?
NCT05198284 is a clinical study titled "Prospective Decision Impact Clinical Utility Trial of KidneyIntelX". The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
What is the current status of trial NCT05198284?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2021-11-01. Estimated completion is 2026-11-01.
What conditions does trial NCT05198284 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Diabetic Kidney Disease, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 1.
What interventions are being tested in trial NCT05198284?
The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05198284?
This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05198284 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05198284's enrollment target sits among peer trials
2,000 3rd of 73 higher than 71 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI